Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

[PDMR] [PDX] [K69424-012-T] Cholangiocarcinoma

ABSTRACT:

SUBMITTER:

PROVIDER: S-CMO4298 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Genomic characteristic PDX in cholangiocarcinoma

Project description:Genomic characteristic PDX in cholangiocarcinoma

| PRJEB63092 | ENA

[PDMR] [organoid] [K69424-012-T-V1-organoid] Cholangiocarcinoma

Project description: Not available

| S-CMO4734 | biostudies-other

Treatment of cholangiocarcinoma using humanized monoclonal antibodies targeting Claudin-1(PDX tumors)

Project description:Cholangiocarcinoma (CCA) is an adenocarcinoma of the hepatobiliary system showing an alarming rise in incidence and mortality with unsatisfactory treatment options. Claudin-1 (CLDN1) is a transmembrane protein expressed in tight junctions and exposed on the cell surface in liver fibrosis and cancer. Using single cell RNA-sequencing (scRNA-Seq) and spatial transcriptomics of CCA patient tissues, we show that CLDN1 expression is highly upregulated in cancer cells and is associated with stemness and cell fate. Gain-of-function studies in CCA orthotopic in vivo mouse models showed decreased survival and enhanced tumor growth, unraveling a functional role of CLDN1 as an oncogenic driver. Targeting exposed CLDN1 using highly specific CLDN1 monoclonal antibodies (mAbs) robustly inhibited tumor growth across CCA CDX and PDX mouse models and patient-derived CCA organoids including tumors with medium or low CLDN1 expression. Moreover, antibody treatment markedly inhibited tumor cell migration, invasion, and extrahepatic metastasis. Mechanistically, targeting exposed CLDN1 on CCA tumors inhibited Notch1, FAK/SRC, and Hippo-YAP signaling, resulting in decreased cancer cell stemness, EMT and extracellular matrix remodeling. In conclusion, these results uncover CLDN1 as a previously undiscovered CCA driver and therapeutic target, paving the way for the clinical development of CLDN1 mAbs to improve the dismal outcome of patients with advanced CCA.

2026-06-08 | GSE261999 | GEO

Experimental design of preclinical experiments: number of PDX lines vs subsampling within PDX lines.

Project description: Not available

| S-EPMC8643474 | biostudies-literature

[PDMR] [PDX] [536437-012-R] Rectal Adenocarcinoma

Project description: Not available

| S-CMO5466 | biostudies-other

Pdx-1 or Pdx-1-VP16 protein transduction induces beta-cell gene expression in liver-stem WB cells.

Project description: Not available

| S-EPMC2637887 | biostudies-literature

Tapencarium (RZL-012) for Flank Fat Reduction: A Proof-of-Concept Study.

Project description: Not available